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Abstract
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Proton beam radiotherapy exposes healthy tissue to stray radiation emanating from the treatment
unit and secondary radiation produced within the patient. These exposures provide no known
benefit and may increase a patient's risk of developing a radiogenic second cancer. The aim of this
study was to explore strategies to reduce stray radiation dose to a patient receiving a 76 Gy proton
beam treatment for cancer of the prostate. The whole-body effective dose from stray radiation, E,
was estimated using detailed Monte Carlo simulations of a passively scattered proton treatment
unit and an anthropomorphic phantom. The predicted value of E was 567 mSv, of which 320 mSv
was attributed to leakage from the treatment unit; the remainder arose from scattered radiation that
originated within the patient. Modest modifications of the treatment unit reduced E by 212 mSv.
Surprisingly, E from a modified passive-scattering device was only slightly higher (109 mSv) than
from a nozzle with no leakage, e.g., that which may be approached with a spot-scanning
technique. These results add to the body of evidence supporting the suitability of passively
scattered proton beams for the treatment of prostate cancer, confirm that the effective dose from
stray radiation was not excessive, and, importantly, show that it can be substantially reduced by
modest enhancements to the treatment unit.
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1. Introduction
Proton therapy is undergoing a rapid technological evolution of beam delivery equipment.
Currently 25 centers worldwide are using protons to treat patients with cancer and other
diseases, and 14 more facilities are planned or under construction (PTCOG, 2007). The main
advantage of proton therapy over photon therapy is that it provides enhanced sparing of
normal tissues from the primary beam in many clinical situations. However, the risks of late
effects from stray radiation, e.g., neutrons and photons, are not yet fully understood (Hall,
2006), particularly those from neutrons. An improved understanding is needed for prostate
treatments in particular because of the high and increasing incidence of prostate cancer and
the large number of patients receiving proton therapy for that disease and because the stray
radiation doses to these patients are expected to be among the largest of all proton treatments
due to the high energy of the initial proton beam.

© 2008 Institute of Physics and Engineering in Medicine

Taddei et al.

Page 2

NIH-PA Author Manuscript

Previous work has shown that the magnitude of stray radiation dose depends on the beam
delivery technique and apparatus, the measurement location, the penetration depth, the field
size, and the spread-out Bragg peak (SOBP) width (Mesoloras et al 2006, Zheng et al 2007).
Measurements and simulations of equivalent dose and ambient dose equivalent from stray
radiation per therapeutic dose (H/D) for passively scattered proton beams have ranged from
<1 mSv Gy−1 to 80 mSv Gy−1 (cf Binns and Hough, 1997, Yan et al 2002, Polf et al 2005,
Zheng et al 2007, 2008). For a spot-scanning beam of 177 MeV protons, Schneider et al
(2002) reported ambient dose equivalent from stray radiation that ranged from 0.9 mSv
Gy−1 to 37 mSv Gy−1, depending on the measurement location in a water phantom.
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Additional investigations have predicted doses from stray radiation during treatment of
specific anatomic structures. Agosteo et al (1998) estimated the absorbed dose from stray
radiation per therapeutic absorbed dose for the treatment of deep tumors with a passively
scattered beam delivery system to range between 0.1 mGy Gy−1 out of the field to as much
as 17 mGy Gy−1 in the field. Jiang et al (2005) estimated whole-body effective doses from
secondary neutrons per therapeutic proton dose of 2.3 mSv Gy−1 for lung tumors and 0.59
mSv Gy−1 for paranasal sinus tumors, of which 36% and 16%, respectively, were from stray
radiation that originated within the patient. For proton treatments of the prostate, Fontenot et
al (2008) found that for a prostate treatment using a passively scattered beam the wholebody effective dose from stray radiation per therapeutic absorbed dose was 7.8 mSv Gy−1
and the ambient dose equivalent per therapeutic absorbed dose at isocenter was 16 mSv
Gy−1. They reported that 40% was from stray radiation originating from within the patient.
Although much effort has been made recently to quantify the magnitude of the stray
radiation, little attention has been paid in the literature to reducing stray radiation doses
through modifications of the treatment apparatus.
The aim of this work was to identify practical methods to reduce the whole-body effective
dose from stray neutron radiation in a patient receiving a passively scattered proton therapy
regimen for cancer of the prostate. In particular, the benefits of using a modified final
collimator, local bulk shields and a supplemental upstream collimator were examined. The
Monte Carlo simulation method was used to evaluate the performance of several such
modifications to a contemporary, commercially available treatment unit.
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2. Methods
2.1. Treatment plan
A treatment plan for a patient that was treated for prostate cancer at our institution was
created using a commercial treatment planning system1 and kilovoltage CT images of the
patient's pelvis. The plan used a lateral-opposed-pair field arrangement (Rossi et al 2004)
with an absorbed dose of 76 Gy prescribed to 100% of the prostate. The prostate also served
as the target volume used in treatment planning. The treatment beam had an energy of 250
MeV (range = 37.9 cm in water) as it entered the nozzle. The beam passed through a range
modulator wheel (Koehler et al 1975) that yielded an SOBP of 11 cm width, a foil that
laterally flattened and spread the beam to generate a 25.5 cm diameter uncollimated proton
1Eclipse Proton Planning, Varian Medical Systems, Inc., 3100 Hansen Way, Palo Alto, CA 94304.
Phys Med Biol. Author manuscript; available in PMC 2014 August 26.
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field, and an adjustable range shifter to produce a water-equivalent range at the surface of
the patient of 27.5 cm. As part of the planning process, a field-specific custom block made
of brass was designed to collimate the treatment beam to cover the target volume. A fieldspecific custom range compensator (Wagner 1982) made of polymethyl methacrylate
(PMMA) conformed the distal edge of the proton dose distribution to the target volume. For
this treatment, a snout setting of a medium snout (i.e., up to 18 × 18 cm2 field size) was
selected. The air gap between the snout and the patient was minimal (<5 cm).
Because the treatment was approximately symmetrical about the patient's medial plane the
two-field plan could be approximated as a single left-lateral beam, where the prescribed
absorbed dose to the target volume (prostate) was maintained at 76 Gy. The plan was
exported for Monte Carlo simulation.
2.2. Monte Carlo modeling of the treatment unit
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Monte Carlo simulations were performed using the Monte Carlo N-Particle eXtended
(MCNPX) code version 2.6b (Pelowitz 2005) with parallel computing methods. The
suitability of the MCNPX code for simulating therapeutic absorbed dose distributions and
secondary radiation related to proton therapy has been established (Fontenot et al 2005,
Herault et al 2005, Koch and Newhauser, 2005, Newhauser et al 2005, Polf and Newhauser,
2005, Polf et al 2005, Tayama et al 2006, Fontenot et al 2007b, Herault et al 2007,
Newhauser et al 2007b, 2007a, Zheng et al 2007, 2008).
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An MCNPX model of a commercial passive-scattering treatment unit2 (Newhauser et al
2007a) in service at The University of Texas MD Anderson Cancer Center (Smith et al
2003) was used in this work. The model used an elliptical proton source positioned
immediately upstream of the nozzle, 3.29 m from isocenter, with a lateral Gaussian intensity
distribution (horizontal FWHM = 5.4 mm, vertical FWHM = 12.2 mm), simulating the
entrance of the parallel beam into the treatment head. The source was modeled with a
Gaussian energy distribution with an initial mean energy of 250 MeV (FWHM = 0.29
MeV). Within the nozzle, dual-scattering foils spread and flattened the beam laterally and a
range-modulating wheel spread the Bragg peak in the direction of the beam axis. The model
included beam monitors, range-shifting plates, structural and housing components (figure 1),
and various static collimators in the treatment head. An 8 cm thick brass collimating
aperture defined the final shape of the field. A field-specific range compensator conformed
the treatment field to the distal surface of the target volume. The major features of the Monte
Carlo model were described previously (Newhauser et al 2007a, Zheng et al 2007).
However, the geometric model of the standard (unmodified) nozzle was extended in this
work to investigate various strategies to reduce effective dose from stray radiation
emanating from the nozzle as described in section 2.3.
2.3. Modeling of the nozzle modifications
Three strategies were tested to reduce neutron exposures: (1) adding bulk shields near the
patient, (2) exchanging the final brass collimator with a tungsten-alloy replacement and (3)

2PROBEAT, Hitachi America, Ltd., 50 Prospect Avenue, Tarrytown, NY 10591.
Phys Med Biol. Author manuscript; available in PMC 2014 August 26.
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adding an upstream proton collimator near the range shifter assembly. The geometry of the
supplemental bulk shields considered in this work is shown in figure 1, and the materials
and dimensions are listed in table 1. This shield comprised two layers; the first layer (item E
in figure 1) was up to 29 cm thick, and the second layer (item F in figure 1) was 6 cm thick,
totaling up to 35 cm of shielding. For the final collimator (item A in figure 1), brass was
replaced with tungsten alloy, a commonly used material for multi-leaf collimators (cf
Maughan et al 1994, Bues et al 2005, Pönisch et al 2006, Jang et al 2006, Tacke et al 2006,
Farr et al 2006, Svensson et al 2007). The upstream collimator (item G in figure 1), also
made of tungsten alloy, was located immediately downstream of the range-shifting plates
(162 cm away from the surface of the patient and 186 cm upstream of isocenter). The
aperture of this additional collimator had the same shape as the aperture of the final
collimator, but its lateral dimensions were reduced to take into account the fact that it was
closer to the virtual source (cf Newhauser et al 2007a). The lateral dimensions of the
aperture were then expanded by 20% to minimize the effects of collimator-scattered protons
on the dose distribution of the therapeutic proton beam (Titt et al 2008).
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In this paper, stray radiation is defined as undesirable scattered radiation that is produced
when the primary (therapeutic) proton beam interacts in the treatment unit or in the patient.
The primary contributor to absorbed dose from stray radiation was secondary neutron
radiation. Secondary neutrons were either generated in the patient or in the treatment unit.
Neutrons generated in the patient, or ‘internal neutrons’, were considered a confounding
factor in all simulations because they could not be attenuated by improvements to the
nozzle. Therefore, to evaluate the performance of each strategy listed above, an ideal nozzle
was modeled, in which all stray radiation that originated in the treatment unit was stopped
immediately upstream of the patient. This was accomplished in MCNPX by placing a thin
and wide cylindrical cell between the nozzle and the phantom with an importance of 0 for
neutrons. The secondary radiation in the case of the ideal nozzle originated solely from
interactions of primary protons inside the patient. Stated another way, by modeling an ideal
nozzle, the lowest dose that could be achieved through modifications to the treatment unit
was estimated. This model was also helpful in interpreting the relative importance of
neutrons generated in the treatment unit, or ‘external neutrons’, and consequently the
proposed modifications to the nozzle.

NIH-PA Author Manuscript

2.4. Modeling of the patient
Because the CT images used for the treatment plan were limited to the pelvic region, they
were replaced in the simulations by a whole-body anatomical male phantom (Billings and
Yucker, 1973) shown in figure 1. This phantom was previously adapted for use with the
MCNPX code by Fontenot et al (2007a). For the purposes of this study, the phantom
matched the size and shape of the patient. Absorbed dose and spectral fluence were sampled
for protons, neutrons, photons and alpha particles in subvolumes of 12 organs of interest.
This was accomplished by using twelve 2 cm diameter, spherical tally volumes, one in each
of the brain, right lung, left lung, stomach, liver, colon, esophagus/thyroid, bladder, rectum,
breast, gonads and prostate (isocenter).

Phys Med Biol. Author manuscript; available in PMC 2014 August 26.
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In each simulation, 109 source protons were tracked along with secondary neutrons, photons,
hydrogen and helium. The total computing time for all the simulations reported in this paper
was 1061 cpu.days when run on 2.6 GHz, 64-bit processors (AMD Opteron)3.
2.5. Reduction in effective dose
For each nozzle modification, the resulting reduction in effective dose was given by

(1)

where Eo was the effective dose for the standard or unmodified nozzle and E was the
effective dose for the modified nozzle. The effective dose was separated into contributions
from the primary (therapeutic) beam and the stray radiation (generated in the nozzle or
patient):

(2)

By substituting equation (2) into equation (1), the reduction in effective dose was
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(3)

In all cases, the dosimetric contributions from the therapeutic (primary) proton beam were
constant by design. This included the organ absorbed doses, organ equivalent doses and the
effective doses. Therefore, Eo,ther was by definition equal to Ether, and equation (3) was
simplified to

(4)
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Thus, for each case, the reduction in effective dose was entirely attributable to a reduction in
stray radiation. In the remainder of this work ΔE will denote the reduction in effective dose
from stray radiation and E will denote the effective dose from stray radiation. Next, the
change in effective dose may be further broken down to distinguish the contributions of
external and internal neutrons.
As stated above, the effective dose from stray radiation had two primary components, that
from external neutrons and internal neutrons. Therefore, the effective dose was separated
into contributions from internal neutrons originating in the patient, Eint, and external
neutrons generated in the nozzle, Eext:
(5)

By substituting equation (5) into equation (4), the following is obtained:

3Advanced Micro Devices, Inc., One AMD Place, PO Box 3453, Sunnyvale, CA 95070.
Phys Med Biol. Author manuscript; available in PMC 2014 August 26.
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Just as Eo,ther was by definition equal to Ether, because the properties of the therapeutic
proton beam were held constant for each case, it followed that Eo,int was equal to Eint.
Equation (6) therefore could be simplified to

(7)

Thus, for each modified nozzle, the reduction in effective dose was entirely attributable to a
reduction in external neutrons.
The performance of the shielding modifications was assessed using two figures of merit.
The purpose of the first figure of merit, E, was to quantify the absolute effective dose from
stray radiation for each particular modification of the standard nozzle. The second figure
was simply the percentage reduction in the effective dose from external neutrons for each
modification of the standard nozzle, or

NIH-PA Author Manuscript

(8)

This figure of merit characterized how well the modified nozzle approached an ideal nozzle.
For example, N was 0% for the unmodified nozzle and 100% for an ideal nozzle, i.e. where
external neutrons were completely eliminated. In equation (8), the numerator was
determined from equation (7), and the denominator was calculated according to

(9)

where Eo was from a simulation of the unmodified nozzle (section 2.3) and where Eo,int was
from a simulation of the ideal nozzle (section 2.3) in which all external neutrons were
eliminated.
2.6. Effective dose from stray radiation
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Following ICRP Publication 92 (ICRP, 2003), E was calculated as the sum over specified
organs or tissues, T,

(10)

where wT denotes the tissue weighting factor and HT denotes the organ equivalent dose from
stray radiation. The values for wT were based on the recommendations from ICRP
Publication 60 (ICRP 1991), and were intended to take into account the relative contribution
to the risks of attributable detrimental effects. The values from ICRP Publication 60 were
adjusted slightly as follows to take into account the large spatial variations of doses
throughout the body from pelvic radiotherapy. The value of wT for lung was split between
Phys Med Biol. Author manuscript; available in PMC 2014 August 26.
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the right and left lungs, with wT = 0.06 for each. An average value of HT for the colon was
calculated using data from the tally subvolumes of the colon and rectum, which was applied
to the recommended wT = 0.12 for the colon. One tally subvolume was used to estimate the
esophagus and thyroid equivalent doses; therefore, the wT values were combined to yield wT
= 0.10 for the subvolume that represented these organs. wT values for the breast, stomach,
bladder, gonads, liver and brain were taken directly from ICRP Publication 60. The average
of HT for all subvolumes was applied as an approximate equivalent dose to the remaining
organs and tissues (e.g., red bone marrow, bone surface, skin, etc), and, together, these
organs had a wT value of 0.19. This follows the calculation approach from Fontenot et al
(2008).
For each organ or tissue, HT was calculated according to
(11)
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where DT was the average absorbed dose from stray radiation in the organ or tissue and
was the mean radiation weighting factor used for all organs and all nozzle configurations as
described below.
The org an-absorbed dose from stray radiation, DT, was approximated by the absorbed dose
calculated in the subvolume, as described above. The DT value was calculated as the sum of
the absorbed dose from all major types of secondary radiation, including protons, DT (p);
neutrons, DT (n); photons, DT (γ); and alpha particles, DT(α). Energy transferred by these
particles to electrons and recoil nuclei was absorbed locally at the interaction point and
included in the appropriate tallies for absorbed dose. Thus,

(12)

where DT was normalized by the calculated absorbed dose to the isocenter subvolume, Diso,
located inside the prostate in the simulation and multiplied by the planned therapeutic dose
of 76 Gy.
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An organ was classified as ‘in-field’ if absorbed dose calculated in the tally subvolume
included a contribution from the primary treatment field. In-field organs with a non-zero wT
included the bladder and the rectum, which had contributions to absorbed dose from primary
protons. The remaining organs with tally subvolumes were classified as ‘out-of-field’
because the absorbed dose in their tally subvolumes resulted entirely from stray radiation.
In calculating DT using equation (12), the determination of the value of DT (p) for infield
organs required special treatment because the MCNPX tallies of absorbed dose did not
distinguish between therapeutic protons and secondary protons that originated from stray
radiation. Specifically, the DT values for in-field organs were dominated by primary protons,
whereas DT was defined as taking into account only stray radiation. Out-of-field organs did
not require special treatment because primary protons did not contribute to absorbed dose to
those organs. Also, distinguishing between therapeutic and stray radiation in out-of-field
Phys Med Biol. Author manuscript; available in PMC 2014 August 26.
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organs was not necessary for other radiation types since they were, by definition, all stray
radiation. The methods for correcting DT (p) values for in-field organs are presented in the
appendix.
A radiation weighting factor, wR, was estimated for each organ and in each simulation based
on the neutron spectral fluence incident on the tally subvolumes and following the
recommendations of ICRP Publication 92 (ICRP 2003). This represents a slight departure
from the methods recommended by the ICRP, in which wR is calculated based on the
neutron fluence external to the body. This approach was developed for radiation protection
applications involving irradiations of the whole body in a nearly uniform field. Instead, in
this work wR was based on the neutron fields inside the body because much of the absorbed
dose resulted from neutrons generated within the body. As will be shown in section 3, the
was
values of wR for each organ varied only slightly. Therefore, for simplicity a mean
used for all organs and all nozzle configurations except for the ideal nozzle.
2.7. Uncertainty

NIH-PA Author Manuscript

The uncertainties in DT, HT, E and ΔE were estimated using standard propagation of
uncertainties on the assumption that the component uncertainties were uncorrelated.
Statistical uncertainties in the values of DT (X) were based on the coefficients of variation,
σ(X)/DT (X), for the tallies of absorbed dose of each particle type X calculated using
MCNPX. The uncertainty in the value of
was set to zero because the variance was small
compared to the implicit uncertainty in the definition of wR, and the uncertainties in wT were
assumed to be zero because these values were set by definition rather than measured within
the study. The uncertainties were reported at the 68% confidence interval.

3. Results
3.1. Effective dose from stray radiation
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Table 2 lists the values of effective dose from stray radiation, E, for the standard nozzle
(with the brass final collimator and no supplemental shielding) (mod0), the standard nozzle
with a tungsten-alloy final collimator (mod1), a modified nozzle with the optimal
supplemental shielding determined by this study (mod2), the modified nozzle with
supplemental shielding and a tungsten-alloy final collimator (mod3), the modified nozzle
with supplemental shielding, a tungsten-alloy final collimator, and an additional upstream
collimator (mod4), and the ideal nozzle (mod5). E for the standard nozzle was 567 mSv. By
replacing the standard nozzle with the ideal nozzle in the simulation, the reduction in E was
320 mSv. This represented the maximum possible reduction in E through improved nozzle
design. This value was important because it provided a benchmark against which to compare
the performance of each modification of the nozzle. It also represented the portion of the
absolute effective dose that was due to external neutrons (56.4%). The standard passivescattering nozzle resulted in a factor of 2.3 higher effective dose from stray radiation than
what might be possible with a spot-scanning system.
Adding the dual-layered shielding to the standard nozzle (mod2) reduced E by 57 mSv. By
replacing the brass final collimator with one made of tungsten-alloy (mod3), E was reduced
by another 19 mSv. Finally, placing an extra tungsten-alloy collimator 186 cm upstream of
Phys Med Biol. Author manuscript; available in PMC 2014 August 26.
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isocenter (mod4) reduced E by an additional 136 mSv and did not alter the characteristics of
the primary proton beam. Thus, modest modifications to the nozzle reduced the effective
dose from stray radiation emanating from the treatment head by 212 mSv, from 567 mSv to
355 mSv (37.4% reduction in E). This corresponded to an N = 66.3% reduction in effective
dose from external neutrons.
The relative contribution to the risks of detrimental effects attributable to stray radiation was
taken into account by multiplying the effective dose from stray radiation by the radiation
weighting factor for each organ, HT wT . Values of HT wT are plotted in figure 2 for the
standard nozzle (mod0), the nozzle with supplemental shielding and a tungsten-alloy final
collimator (mod3), the same modifications plus an extra upstream collimator (mod4) and the
ideal nozzle (mod5). Contributions to risk were highest in the rectum, bladder, gonads and
stomach. HTwT was heavily influenced by the wT values, e.g., it was much higher for gonads
than for bladder or rectum.
3.2. Organ equivalent dose from stray radiation
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Figure 3(a) shows the values of equivalent dose from stray radiation for each organ, HT,
using these same four nozzle configurations. For the standard nozzle (mod0), HT for each
organ varied from 0.08 Sv to 1.5 Sv, depending on the distance from the organ to isocenter.
The rectum and bladder had the highest HT values at 1.5 Sv each. Even with the ideal nozzle
(mod5) the rectum and bladder still received about 0.9 Sv of equivalent dose from internal
neutrons. It should be noted that, because the bladder and rectum are adjacent to the
prostate, the equivalent dose from primary protons was much larger than the equivalent dose
from stray radiation.
Figure 3(b) shows the reduction in HT achieved after modifications were applied to the
standard nozzle. Adding supplemental shielding and exchanging the brass final collimator
with a tungsten-alloy replacement (mod3) reduced HT by less than 5% for the in-field
organs. Because of the shape of the shielding (as shown in figure 1), the available space for
supplemental shielding was smallest for the in-field organs. Supplemental local shielding
clearly reduced HT for the out-of-field organs because the shielding thickened with off-axis
distance. Organs farther from isocenter were largely spared from stray radiation when
shielding was added.
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When the steel and PMMA layers of shielding were added, the final collimator material was
changed to tungsten alloy, and an upstream collimator was included (mod4), HT was
reduced for all organs. The organs that were partially in the proton field (i.e., rectum and
bladder) had a marked reduction in HT, approximately 18%. Organs that were characterized
as out-of-field but were within 35 cm of isocenter (i.e., gonads, colon, liver and stomach)
had even larger percentage reductions in HT (33% to 72%). For organs more than 35 cm
from isocenter (i.e., breast, lungs, esophagus, thyroid and brain), HT was reduced by more
than 72%.
For all tally subvolumes (including isocenter) and all nozzle configurations, excluding the
was 5.9 ± 0.2. The maximum value of wR was 7.38 and the
ideal nozzle, the mean value
minimum value was 4.55.

Phys Med Biol. Author manuscript; available in PMC 2014 August 26.
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3.3. Local bulk shielding selection
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Six configurations of supplemental shielding were tested, with one case having two layers of
different materials (as shown in figure 1). For each case, ΔE is shown in figure 4. For lowdensity shielding materials, such as PMMA, polyethylene and concrete, relatively small ΔE
values were observed. In the case of polyethylene, adding boron as a thermal neutron
absorber to the material composition did not significantly reduce E because thermal neutrons
contributed only a small proportion to HT (Yan et al 2002, Zheng et al 2008). When
relatively high-density steel was used for the first layer of supplemental shielding, E was
reduced considerably more than when PMMA was used for both layers. Also, a layered
configuration of high-density steel (density = 7.9 g cm−3) and hydrogenous PMMA (8%
hydrogen by mass) reduced E slightly more than high-density material alone. Because it had
the largest ΔE and appeared to be practicable, the dual-layered shielding design, with highdensity steel as the first layer and hydrogenous PMMA as the second layer, was selected to
be analyzed further in the study (mod2).

4. Discussion
NIH-PA Author Manuscript

Monte Carlo simulations suggest that it may be possible to reduce the effective dose from
stray radiation emanating from the treatment unit, or external neutrons, by approximately
66% for patients receiving passively scattered proton therapy for prostate cancer. In the
simulations, this corresponded to a 37% reduction in the absolute effective dose from stray
radiation originating in the treatment unit and the patient. This result approaches what may
be achieved through alternative nozzle designs, for example a nozzle that implements a spotscanning technique. The reduction was achieved with the following modest modifications,
listed in descending order of effectiveness: (1) adding a proton collimator far upstream from
the patient, (2) using tungsten alloy in place of brass for the final collimator and (3)
increasing local shielding near the patient. The results revealed that the performance of
supplemental local shielding can be increased by using a high-density layer along with a
hydrogenous layer.
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The effective dose from stray radiation per therapeutic absorbed dose, E/D, was similar to
that reported in previous studies. The predicted E/D value for the standard nozzle was 9.2
mSv Gy−1. This is in good agreement with previous H/D determinations made in the
presence of a phantom. Specifically, measured H/D values from Yan et al (2002) and
simulated H/D values from Polf et al (2005) and Zheng et al (2008) ranged from 1 mSv
Gy−1 to 15 mSv Gy−1, depending on the location and other variables.
In this study, the component of E/D that was from external neutrons was 5.2 mSv Gy−1.
This value is consistent with the H/D values calculated by Zheng et al (2007) for a 250 MeV
beam without a phantom present, which ranged from 1 mSv Gy−1 to 20 mSv Gy−1 within
120 cm of isocenter. This value was less than the measured H/D values reported by Binns
and Hough (1997) for a pre-clinical nozzle, which were between 33 mSv Gy−1 and 80 mSv
Gy−1. However, the results from Binns and Hough are the highest H/D values in the
literature, and the differences with respect to the present work are likely due to the
considerable differences in the treatment units.

Phys Med Biol. Author manuscript; available in PMC 2014 August 26.
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It was determined that 43% of E/D for the standard nozzle was from internal neutrons. This
result is similar to the effective dose from internal neutrons that was reported by Fontenot et
al (2008) for a prostate treatment (40%) and by Jiang et al (2005) for a lung treatment
(36%).
The recommended risk coefficient of the NCRP (1997) for low-dose-rate, exposure-induced
death for middle-aged men is 4.2% per Sv. Applying this risk coefficient to the reduction in
effective dose from stray radiation in this study, the adoption of the three-part strategy
described here (i.e., additional upstream collimator, supplemental bulk shielding and a final
collimator of tungsten alloy) would result in approximately 9 fewer second cancer fatalities
per 1000 patients undergoing passively scattered proton therapy for prostate cancer.
The scope of this study was to investigate whether simple methods could be used to reduce
stray radiation exposure for patients undergoing proton therapy for prostate cancer. The
results of this study suggest that such modifications are feasible and effective. In addition, it
appears likely that the effectiveness and compactness of these enhancements may be
substantially optimized relative to the nozzle designs unique to each proton therapy facility.
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Existing facilities for high-energy neutron therapy may serve as models for designing future
passively scattered proton treatment units to minimize stray radiation exposure. For
example, the most promising modification to the nozzle, and potentially the simplest and
least expensive, was the addition of a field-specific pre-collimator located far upstream from
the patient. One suggestion might be to implement this strategy using a computer-controlled
multi-leaf collimator fashioned after the multi-leaf collimators currently being used with
intensity-modulated radiation therapy (Bues et al 2005, Pönisch et al 2006, Jang et al 2006,
Tacke et al 2006), as is already being done at some facilities. For instance, the neutron
therapy facility at the University of Washington employs a computer-controlled steel and
polyethylene multi-leaf collimator (Brahme et al 1983). The use of both a manually
controlled tungsten multi-rod collimator and a computer-controlled steel multi-leaf
collimator for attenuating fast neutrons was investigated at the Harper Hospital in Detroit,
MI (Maughan et al 2001, Farr et al 2006); it was determined that both steel and tungsten are
suitable materials for fast neutron attenuation and had acceptable activation levels (the
former is cheaper, but the latter has a higher linear attenuation coefficient). A passively
scattered nozzle at the Proton Medical Research Center at the University of Tsukuba (Japan)
uses a brass multi-leaf collimator to remove non-therapeutic protons from the beam. The
spot-beam-scanning system at the National Institute of Radiological Sciences in Chiba,
Japan uses a backup multi-rod collimator made of brass (Tsunemoto et al 1985).
Reinforcing the idea of incorporating a variable multi-leaf collimator in nozzle design is the
work by Tayama et al (2006), who investigated the effect of changing the aperture size of a
pre-collimator on dose equivalent from stray neutrons emanating from the nozzle. By
changing the aperture from 220 mm to 54 mm, the H/D value was reduced by more than
40% for locations within 80 cm trans-axially of isocenter. This evidence further suggests
that adding an adjustable pre-collimator far upstream of the patient may be critical in
reducing stray radiation dose to patients undergoing proton therapy. This pre-collimator
would serve to both stop non-therapeutic protons and move the effective neutron source to a
greater distance from the patient.
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The types of materials used for these modifications may also be optimized for each facility.
Neutron therapy facilities have used pressed wood (Bonnett et al 1980) and iron (Maruyama
et al 1978) to moderate and attenuate high-energy neutrons. Osmium has also been
suggested as a collimator material for light ion beams (Svensson et al 2007). The Monte
Carlo simulations performed in this work may serve as a model for optimizing shielding
materials for specific facilities.
The present study had some limitations. In particular, one factor that may have introduced
systematic error was the method for estimating dose from secondary protons for organs,
where the total dose was dominated by primary protons (described in the appendix). The
correction for determining absorbed dose from stray radiation for the bladder and rectum
introduced uncertainties that were very difficult to quantify. However, since the combined
wT for these organs was only 0.11, this approximation was of minor importance since it had
minimal effects on the predicted ΔE values.
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There was also inherent uncertainty in applying the physical dosimetric quantities to
estimate the risk of biological effects. The definition of wR used in this study was applied to
fast and high energy neutrons, but at present the relative biological effectiveness of these
neutrons is uncertain. For neutron-induced carcinogenesis, relative biological effectiveness
may be as much as 50 (Wolf et al 2000), 100 (Shellabarger et al 1980) or more than 100
(Kellerer et al 2006) at low doses. If the values of wR were modified, the quantities of
effective dose would scale linearly with the value of wR. However, since the second figure
of merit of this study was reported in terms of the percent reduction in effective dose using a
, it would remain the same at different wR values. Therefore, this is not a serious
constant
limitation.
In conclusion, this Monte Carlo study establishes the viability of implementing modest
modifications to a standard passively scattered proton treatment unit in order to reduce
markedly the whole-body effective dose from stray radiation in a patient receiving proton
radiotherapy for prostate cancer.
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Appendix. Approximation for DT(p) of in-field organs
For out-of-field organs, the values of DT(X) for each particle type X were assumed to be
entirely from stray radiation. For in-field organs, this assumption was not valid because
primary, therapeutic protons had a much larger contribution to DT(p) than protons produced
from stray radiation. Therefore, for in-field organs, an alternative approach was used to
determine DT (p).
applied to each DT and a constant set of values of wT applied in each
For a constant
configuration, equations (3), (10) and (11) in the main text were combined to derive
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where ΔDT,i was the change in absorbed dose to an organ or tissue for each nozzle
configuration, i. The relative uncertainty in ΔDT,i was

(A.2)

For the out-of-field organs,
was small (< 0.10). For in-field organs, however, just as
DT,o,ther and DT,i,ther were much larger than DT,o,stray and DT,i,stray, σΔDT,o,ther and
σΔDT,i,ther were much larger than σΔDT,o,stay and σΔDT,i,stray. As a result, although the large
values of therapeutic dose canceled in the denominator, their large uncertainties were added

NIH-PA Author Manuscript

to be large. This large coefficient of variance would have
in the numerator, causing
been propagated to higher-order quantities of HT, E and ΔE.
Therefore, an alternative approach was developed to provide reasonably small uncertainties
in absorbed dose for the in-field organs. Applying equation (4) of the main text, the values
for therapeutic absorbed dose and their uncertainties were assumed to be zero, and the
absorbed dose tallies for neutrons, photons and alpha particles were all assumed to be from
stray radiation. The absorbed dose tally for protons in MCNPX did not distinguish between
primary and secondary protons. Therefore, the contribution to absorbed dose from primary
and secondary protons was not separated, and DT(p) was not obtained from the tally.
Instead, the following methods were used to determine DT(p).
The values of DT(p)/DT(n) were analyzed for all out-of-field organs and all configurations,
excluding the ideal nozzle. The analysis showed that DT(p)/DT(n) was independent of the
distance of the organ from isocenter (data not shown). The mean of the ratio of absorbed
dose from secondary protons to that from secondary neutrons, A, was given by
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(A.3)

and was determined for the nine out-of-field organs, T, in the nine nozzle configurations, i,
excluding the ideal nozzle. For the in-field organs, the absorbed dose from stray proton
radiation was approximated as

(A.4)

Thus, for the in-field organs, equation (12) became
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This approach ensured that DT included only absorbed dose from stray radiation. The
resulting value of A was 5.7 ± 0.2.
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Figure 1.

Anatomical models of a man in the treatment position and the treatment nozzle. The portion
of the treatment head near the patient shows the final collimator (A), range compensator (B),
snout (C) and other collimators (D). The phantom was arranged to represent the patient in
the treatment position. Shielding layers one (E) and two (F) were added between the nozzle
and the patient. An additional tungsten-alloy pre-collimator (G) in the same shape as the
final collimator but appropriately scaled in the lateral dimensions was placed 186 cm
upstream of isocenter. The projections of the locations of the tally subvolumes onto the
displayed plane are shown as black circles on the phantom.
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Figure 2.

The product of the equivalent dose from stray radiation and the tissue weighting factor, HT
wT , for each organ in simulations of the standard nozzle (mod0) (solid squares), a nozzle
equipped with supplemental shielding and a tungsten-alloy final collimator (mod3) (solid
circles), the equipped nozzle with an additional collimator far upstream of the patient
(mod4) (open squares) and the ideal nozzle (mod5) (open circles). The values represent the
relative contribution to effective dose and risks of detrimental effects. The lines were added
to guide the eye. Distance from the organ to isocenter increases from left to right on the plot.
These data were for a 76 Gy SOBP proton treatment of the prostate. Statistical uncertainties
in values of HTwT are contained within the data markers.
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(a) Equivalent dose from stray radiation, HT, for each organ in simulations of the standard
nozzle (mod0) (solid squares), a nozzle equipped with supplemental shielding and a
tungsten-alloy final collimator (mod3) (solid circles), the equipped nozzle with an additional
collimator far upstream of the patient (mod4) (open squares) and the ideal nozzle (mod5)
(open circles). (b) Percent reduction in HT for each modified case. The lines in both (a) and
(b) were added to guide the eye. Distance from the organ to isocenter increases from left to
right on the plots. Error bars represent the 68% confidence interval. Where error bars are not
shown, statistical uncertainties were contained within the data markers.
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Figure 4.

Reduction in effective dose from stray radiation for various supplemental shielding materials
for a 76 Gy SOBP proton treatment of the prostate. The supplemental shielding was added
in two layers to the standard nozzle. For the ‘steel + PMMA’ case (mod2), the two
supplemental layers were configured with the steel layer upstream of the PMMA layer.
Error bars represent the 68% confidence interval.
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Configurations of supplemental shielding that were added to the standard nozzle and evaluated with simulated
SOBP treatments. The configurations were defined by the composition of the two layers of supplemental
shielding. Layers 1 and 2 are shown as items E and F, respectively, in figure 1. Also listed are the masses of
each dual-layer combination (PMMA is polymethyl methacrylate)
Supplemental shielding
Layer 1

Layer 2

Mass (kg)

Polyethylene

Polyethylene

307

Borated polyethylene

Borated polyethylene

311

PMMA

PMMA

389

Concrete

Concrete

765

Steel

PMMA

2067

Steel

Steel

2567
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None

None

Steel

Steel

Steel

0

1

2

3

4

5

Layer 1

Mod

PMMA

PMMA

PMMA

None

None

Layer 2

Supplemental shielding

Ideal nozzle

Tungsten alloy

Tungsten alloy

Brass

Tungsten alloy

Brass

Final collimator

Yes

No

No

No

No

Additional collimator

247 ± 4

355 ± 5

491 ± 5

510 ± 5

533 ± 5

567 ± 3

E (mSv)

100

66.3

23.8

17.8

10.6

0

N (%)

Values of effective dose from stray radiation, E, for a 76 Gy, SOBP prostate treatment for the standard nozzle (control case), the standard nozzle with a
tungsten-alloy final collimator, the standard nozzle modified with supplemental shielding, a nozzle equipped with the supplemental shielding as well as a
tungsten-alloy final collimator, the equipped nozzle with an additional upstream collimator positioned far upstream of the patient and an ideal nozzle. The
final column, N, is the percent reduction in effective dose from external neutrons. The modifications are indexed in the first column
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